Boost irradiation

RADIATION3 trials

Sponsors

Arbeitsgemeinschaft medikamentoese Tumortherapie, European Organisation for Research and Treatment of Cancer - EORTC, Ruijin Hospital

Conditions

Breast CancerSquamous Cell Carcinoma of the Hypopharynx Stage IIISquamous Cell Carcinoma of the Hypopharynx Stage IVSquamous Cell Carcinoma of the Larynx Stage IIISquamous Cell Carcinoma of the Larynx Stage IVSquamous Cell Carcinoma of the Oral Cavity Stage IIISquamous Cell Carcinoma of the Oral Cavity Stage IVSquamous Cell Carcinoma of the Oropharynx Stage III

Phase 2

Induction Chemotherapy With TP+5-FU or TP+Cetuximab Followed by Radioimmuptherapy for Locally Advanced or Not Resectable SCCHNN

CompletedNCT01884259

Arbeitsgemeinschaft medikamentoese TumortherapieSquamous Cell Carcinoma of the Hypopharynx Stage III, Squamous Cell Carcinoma of the Hypopharynx Stage IV, Squamous Cell Carcinoma of the Larynx Stage III +5

Start: 2013-05-31End: 2022-01-13Updated: 2022-05-26

Boost Irradiation to the Supraclavicular Area Among High Risk cN3c Breast Cancer Patients

RecruitingNCT06404697

Ruijin HospitalBreast Cancer

Start: 2024-05-31End: 2030-04-30Target: 24Updated: 2024-05-08

Phase 3

Randomized Boost Versus no Boost Irradiation of Early Breast Cancer

CompletedNCT02295033

European Organisation for Research and Treatment of Cancer - EORTCBreast Cancer

Start: 1989-05-31Updated: 2014-11-19

Related Papers

Prognostic Factors for Local Control in Breast Cancer After Long-term Follow-up in the EORTC Boost vs No Boost Trial

JAMA Oncology2016-09-08139 citations

Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial.

2014-12-09426 citations